Google to work with Sanofi on diabetes research

Leading diabetes medication makers Sanofi will be working with Google in the near future on the monitoring and treatment of the condition. In the near future this Google Live Sciences division will be split off into its own company under Alphabet. For now, it's still inside Google. Google Live Sciences is currently led by Andrew Conrad who suggests that this Sanofi partnership is just one of many made in the recent past to grow Google Life Science's involvement in medication, software, medical devices, and computing infrastructure.

According to Olivier Brandicourt, MD, Chief Executive Officer, Sanofi, both Google Life Sciences and Sanofi "have both an obligation and a commitment to provide integrated solutions for people living with diabetes."

"This initiative combines Sanofi's strength and knowledge in diabetes with Google's leadership in technology and analytics to create a first-of-its-kind initiative with the potential to transform diabetes care."

As it is with many Google and Google-related project (like Google On and OnHub, for example), Google wants to make this diabetes situation easier to handle. "Together with Sanofi, we believe diabetes management can be simpler and more convenient, which may help patients achieve an improved quality of life," said Andy Conrad, CEO of the life sciences team at Google.

Google and Sanofi will work to improve care and outcomes for people with type 1 and type 2 diabetes. The companies will find new ways to create new tools that integrate "previously siloed pieces of diabetes management", including health indicators such as blood glucose and hemoglobin A1c levels, patient-reported information, medication regimens and sensor devices.